Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The CMV envelope pentamer complex is a five-protein assembly found on the surface of HCMV virions, consisting of the viral glycoproteins gH, gL, UL128, UL130, and UL131A. This complex is critical for the virus’s ability to infect epithelial, endothelial, and myeloid cells, as it binds specific host cell receptors (such as neuropilin-2/NRP2), facilitating viral entry through a series of receptor-mediated steps and membrane fusion. The pentamer is a major antigenic target for neutralizing antibodies, and its structure and antigenic sites are well-characterized—making it a focal point for HCMV vaccine development and monoclonal antibody therapeutics. Blocking pentamer-receptor interactions with antibodies can prevent infection, underscoring the complex’s importance as a therapeutic target. It does not act as a conventional human receptor, enzyme, or transporter, but as a viral fusion and entry complex.
Neutralizing antibodies prevent virus entry by blocking pentamer interaction with cellular receptors Immunization triggers antibody production targeting the pentamer, conferring immunity
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human cytomegalovirus envelope pentamer complex (HCMV pentamer).